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A Ab bs st tr ra ac ct t    Low surface HLA-DR expression is a feature in sepsis. However, the mechanisms 
that regulate HLA-DR expression have not been elucidated. The current study 
investigates regulation of HLA-DR gene transcription, post transcriptional 
events and shedding of  surface HLA-DR, as well as the regulation of HLA-DR by 
GM-CSF and an immunomodulatory cytokine. Plasma and PBMC were collected 
from septic patients and healthy volunteers. An ELISA was developed to measure 
soluble HLA.  PCR techniques were used to determine HLA-DR mRNA levels, 
and flow cytometry and fluorescent microscopy were used for measurement of 
surface expressed and intracellular HLA-DR. Septic patients fulfilling the criteria 
of the American College of Chest Physicians (ACCP) for sepsis were recruited for 
the study  (n=70). HLA-DR was measured on three consecutive days, days seven 
and fourteen. Patients were excluded from the study if on immunosuppressive 
therapy.  Results: Higher levels of shed HLA-DR were found in the plasma of 
septic patients compared to healthy controls. The level of HLA-DR mRNA was 
significantly lower in septic patients compared to healthy controls, however an 
increased intracellular HLA-DR expression was observed. When HL-60 cells 
were treated with GM-CSF, gene transcription, surface expression and shedding 
of HLA-DR were all up-regulated.  These results indicate that the mechanisms 
i n v o l ve d  i n  t h e  r eg u l a t i o n o f  H L A - D R  i n  s ep s i s  in c l u d e  s h e d d i n g  o f  H L A - DR 
from the cell surface and regulation of HLA-DR gene transcription. Post-
translational processing of HLA-DR was also seen to be compromised. GM-CSF 
was shown to regulate HLA-DR at all these levels. 
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1.  Introduction 
Impaired monocyte function has been described in sepsis and has been characterised by inadequate 
respiratory burst, activation, antigen presentation and lowered expression of Human Leukocyte 
Antigen-DR (HLA-DR) [1;2]. HLA-DR is a glycosylated cell surface transmembrane protein expressed 
on antigen-presenting cells and constitutively expressed on monocytes. Expression of HLA-DR by 
monocytes is essential for the presentation of peptides derived from ingested microbes to CD4 positive 
T cells to initiate a specific immune response [3]. Low monocyte surface expression of HLA-DR is a 
feature of sepsis [3-8], however the mechanisms for this reduced surface expression of HLA-DR have 
not been established. Possibilities include down regulation of gene transcription resulting in reduced 
mRNA production, and/or post-translational modification of HLA-DR affecting processing to the cell 
surface. Alternatively, HLA-DR could be cleaved from the monocyte surface and shed into the 
circulation in a soluble form. Higher levels of soluble HLA-DR (sHLA-DR) have been detected in 
plasma and synovial fluid in hyperinflammatory states [9] and in vitro experiments have shown that the 
inflammatory cytokine IFN-γ induced shedding of HLA-DR by human monocytes [10]. However 
whether this type of mechanism is responsible for depressed monocyte HLA-DR in sepsis is not 
established, as one report found plasma HLA-DR to be lower rather than raised in septic patients who 
had a down regulated surface expression [11]. Recently, the regulation of HLA-DR at the level of gene 
transcription has been investigated in patients with sepsis, this correlated with high cortisol levels and 
was thought to be acting on the down regulation of HLA-DR mRNA by also lowering the CIITA [12] 
IFN-γ  has also been shown to regulate transcription of the HLA-DR gene on melanoma cell lines [13]. 
Recently a post-translational modification of HLA-DR was described in septic patients which may be 
responsible for the lowered monocyte surface expression of HLA-DR observed in these septic patients 
[14].  
Lowered HLA-DR expression has been associated with impaired monocyte function and restoring 
expression to normal levels has been proposed to be beneficial [3]. A candidate factor for activating 
monocytes and restoring functional indicators is granulocyte macrophage colony stimulating factor 
(GM-CSF). GM-CSF is a 22-kDa glycoprotein cytokine secreted by mononuclear leukocytes including 
monocytes. It functions as a growth and differentiation factor for immature phagocytic cells and 
clinically it is used to enhance reconstitution of the haemopoietic system, for example following 
chemotherapy [15]. In addition to this, GM-CSF has been demonstrated to enhance the capability of 
monocytes and macrophages to phagocytose invading pathogens [16]. GM-CSF treatment of septic 
patients’ lymphocytes ex vivo has been shown to restore function in anergic monocytes [2]. It has been 
shown that GM-CSF induces monocyte activation [17] and can protect monocytes from becoming 
apoptotic [2]. Clinically, recombinant human GM-CSF has been shown to be effective in the treatment 
of neonatal sepsis [18] with neutropenia [19]   
We have previously shown that monocyte HLA-DR surface expression was upregulated in short 
term culture with GM-CSF and that low plasma levels of GM-CSF were an indicator of poor prognosis 
in sepsis [20]. In the present study we have investigated whether GM-CSF could be a factor in 
regulating HLA-DR expression in PBMC from patients with sepsis. 
2.  Methods 
Patient Selection 
Ethical approval for the study was obtained from the Liverpool Research Ethics Committee. This 
was a single centre study at a medico-surgical adult Intensive Care Unit (ICU) of the Royal Liverpool 
University Hospital. All critically ill septic patients admitted to the ICU who were recruited were 
expected to stay in the ICU for at least 72 hours, not expected to die within 24 hours and fulfilled the 
consensus conference criteria for sepsis [21]. Assent was obtained from next of kin if patients 
themselves were unable to consent into the study. Patients were excluded from the study if any of the 
following criteria were applicable: patients who were septic for greater than 72h; patients who were 
immunosuppressed due to prednisolone therapy >5 mg per day or equivalent, (excluding inhaled 
steroids); patients with clinically suspected or confirmed acquired immunodeficiency syndrome, 
hepatitis B or C; granulocyte count less than 1000 per mm
3 due to a cause other than severe sepsis. Also 
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death within three months from study entry were excluded. Healthy volunteers (n=45) were included as 
controls. The control group consisted of laboratory staff, median age 32. Mortality and focus of sepsis 
are described in the previous study [22]. 
Sample preparation and flow cytometry 
Arterial blood was collected from septic patients on the day sepsis was diagnosed (day 0) and on 
days 3, 7, and 14 for PCR studies and days 0, 1, and 2 for measurement of soluble HLA-DR. Blood (7.5 
ml) was collected in preservative free heparin (final concentration of 100 iu/ml) and cells were prepared 
immediately. PBMC were isolated by density centrifugation using Ficoll Paque (Pharmacia Biotech, 
Sweden). Briefly, whole blood was layered onto an equal volume of Ficoll and centrifuged at 400xg for 
20 minutes at 18˚C. Following isolation and washing of the PBMC viability was assessed to greater 
than 95% using trypan blue exclusion and the PBMC were adjusted to a concentration of 1x10
6 
PBMC/ml. 
Flow cytometric analysis was carried out on Coulter Epics Flow Cytometer. PBMC were dual-
labelled with a mouse IgG anti-human HLA-DR with a fluorescein isothiocyanate (FITC) conjugate, 
clone L243 (Becton Dickinson, UK) and with a mouse IgG anti-human CD14 R-phycoerythrin 
conjugate (R-PE), clone M5E2, (Becton Dickinson, UK) to identify monocytes. Briefly 100 µl of cells 
were incubated with 5 µl of neat antibody for 30 minutes at 4˚C in the dark, washed and resuspended in 
0.5 ml of PBS. For intracellular measurement of HLA-DR the PBMC were fixed for 10 minutes in 1% 
paraformaldhyde, washed in PBS and then incubated in saponin buffer (0.04% EGTA; 0.02% NaN3; 
1% heat inactivated FCS; 0.1% saponin in PBS) before incubation with antibody as above.  [All 
products from Sigma, UK unless mentioned otherwise]. Both the percentage of cells expressing HLA-
DR on monocytes and the density of HLA-DR was measured. 
Immuno-fluorescent microscopy of HLA-DR in PBMC 
Cytospins of PBMC obtained from healthy controls and septic patients were used for observation 
of intracellular and surface staining of HLA-DR. The cytospins were fixed with 4% paraformaldehyde 
(Sigma, UK) and, after a brief wash in PBS, for those samples which required permeabilisation, the 
slides were immersed in methanol (which had been cooled for 1 hour at –20°C, and incubated at –20°C 
for 5-10 minutes. Following washing, the slides were incubated in the dark for 40 minutes at room 
temperature with the mouse IgG anti-human HLA-DR-FITC. Slides were washed thoroughly and a 
fluorescent mounting medium was added (Vectorshield, Vector Labs, UK) .Coverslips were placed and 
sealed with nail hardener and viewed by fluorescent microscopy (BioRad, UK). 
RNA preparation and polymerase chain reaction (PCR) 
From the isolated PBMC, 1x10
6 cells were resuspended in TRIzol (Gibco Life Technologies, UK) 
and RNA extracted following manufacturer’s directions (Invitrogen, UK). Reverse transcription was 
carried out using ImpromII reverse transcriptase (Promega, UK) on 1 µl of RNA following 
manufacturer’s directions to make a cDNA template. The reverse transcribed product (1µl) was used for 
PCR. Primers were designed complementary to a 404 base pair product in the non-polymorphic region 
of the alpha chain of HLA-DR. For each sample, two reactions were set up; one containing reverse 
transcriptase positive product and one reverse transcriptase negative product. This allowed 
identification of DNA contamination. The sequence of the amplified primer product revealed homology 
to the primer target sequence. The primers were designed using Primer Select software (DNA Star). 
Forward HLA-DR Primer: ATCATGACAAAGCGCTCCAACTAT 
Reverse HLA-DR Primer: GATGCCCACCAGACCCACAG (Sigma, UK) 
Soluble HLA-DR measurement by ELISA 
Ninety six well ELISA plates (Nunc, Denmark) were coated overnight at 4˚C with a monoclonal 
mouse anti-human HLA-DR antibody, clone G46-6 (Pharmingen, UK) at a concentration of 1 µg/ml in 
0.05M carbonate buffer, pH 9.6. Following washing in PBS Tween, protein binding sites were blocked 
with 1% skimmed milk powder in PBS, and the washing step repeated. 
Standards (purified HLA-DR) were kindly donated by Dr S Jurcevic. Standard concentrations 
began at 2.5µg/ml, as this was the upper limit concentration in patient samples or in the supernatant of 
cultured HL-60 cells with GM-CSF. Samples were added undiluted and at 1 in 10 dilution, in duplicate. Int. J. Med. Sci. 2004 1(3): 126-136  129 
Following an incubation and washing, the primary detection antibody was added, a mouse anti human 
IgG1 anti-HLA-DR (CR3/43) (Dako, Denmark), at a concentration of 1 µg/ml. After a 2h incubation at 
room temperature, plates were washed and the secondary detection antibody was added, 100µl of 
biotinylated anti-mouse IgG1 antibody at a concentration of 2ug/ml (Pharmingen, UK). Following a 2h 
incubation plates were washed and 100µl of avidin peroxidase conjugate (1/1000) was added to each 
well and incubated for 30 minutes at room temperature. Plates were washed thoroughly, then 50µl per 
well of chromogen/substrate (0.3mg/ml of 2, 2’-azino- bis [3-ethylbenzthiazoline-6-sulfonic acid] 
containing 0.02% hydrogen peroxide in 0.1M citrate buffer pH 6.0, [ABTS] Sigma, UK) was added 
following manufacturer’s directions and incubated at room temperature until colour development. 
Absorbance was then read at 405 nm on an ELISA plate reader. 
HL-60 cell line maintenance and culture 
HL-60 cells, a human promyelocytic cell line, were maintained in complete RPMI (10% FCS, 
20mM L-glutamine, 20U/ml penicillin, 100ug/ml streptomycin). HL-60 cells (5 x 10
5 cells/ml) were 
cultured with GM-CSF at concentrations of 1ng/ml and 10ng/ml At time points 4, 6, and 8 hours, cells 
were evaluated for surface expression of HLA-DR and HLA-DR mRNA production.  Control samples 
were included where cells were incubated in complete RPMI 1640 medium alone. 
HL-60 cells (200 µl) were taken from the well, pelleted down at 5000 x g for 30 seconds, washed 
twice in PBS, then incubated with 2.5 µl of PE labelled anti-human HLA-DR antibody (Pharmingen, 
UK) as already described above. HLA-DR mRNA was measured as described previously. Supernatants 
from the cell cultures with GM-CSF were stored at –70ºC and assayed for sHLA-DR as described 
earlier. 
Western Blotting for sHLA-DR in cell lysates and plasma 
Cell lysates of protein were prepared from PBMC of septic patients and healthy volunteers. Protein 
was extracted by resuspended 2x106 PBMC in protein lysis buffer (50mM HEPES [pH 7.2], 150mM 
NaCl, 5mM EDTA, 0.5% NP-40) containing a cocktail of mammalian protease inhibitors (Sigma, UK). 
The PBMC were centrifuged after a 10 minute incubation on ice and the resultant supernatant contained 
the protein extract. 
HLA-DR standard, cell lysates and plasma samples were separated using a Mini-PROTEAN® II. 
The separation gel was a 14% polyacrylamide gel (National Diagnostics, Georgia) prepared following 
manufacturer’s directions. 
The cells lystes were used at a 1 in 10 dilution, plasma samples were run neat in the native, 
unreduced, state. Standard molecular weight markers were run, (132, 90, 55, 43, 34, 23)  (Cruz marker, 
Santa Cruz Biotech, CA). After SDS-PAGE, transfer of proteins was carried out using the Mini Trans-
Blot® Electrophoretic Transfer Cell (Bio-Rad, UK) and the membrane was blocked (5% skimmed milk 
powder, 0.05% Tween in TBS). A monoclonal mouse IgG1anti human anti-HLA-DR [CR3/43] was 
added at a concentration of 1ug/ml (Dako, Denmark), the membranes were then washed, and incubated 
with the secondary detection antibody, a Cruz Marker-Compatible Secondary Antibody (Santa Cruz 
Biotech, CA), an HRP conjugated goat anti mouse IgG for HLA-DR detection. The membranes were 
developed using Western Blotting Luminol Reagent (Santa Cruz Biotech, CA) followed by exposure to 
Hyperfilm (Amersham, UK).  
Statistical analysis 
The Shapiro Wilk test was applied to test for normally distributed data. For non-parametric data, 
the Mann-Whitney U test was applied to compare two independent samples when test data were 
compared directly with control data. The Kruskall Wallis one-way ANOVA was applied to data where 
more than two independent samples were compared with each other. The Friedman test and the R
2 
correlation coefficient was applied to identify significant trends. In normally distributed paired sets of 
data the paired Students T Test was applied. 
3.  Results  
PCR analysis of HLA-DR mRNA in septic patients versus healthy controls Int. J. Med. Sci. 2004 1(3): 126-136  130 
HLA-DR mRNA was measured in 8 healthy controls by PCR. The mRNA bands were semi-
quantitated using densitometry software which gave a numerical value.  
HLA-DR mRNA was measured in the septic patients, on days 0, 3, 7 and 14, if patients survived 
until day 14. The densitometry values for mRNA of the healthy controls were compared to the values of 
the septic patients on each day. Figure 1 shows HLA-DR mRNA for septic patients monocytes was 
significantly lower than in healthy controls (day 0 p = 0.02, day 3 p= 0.05). 
Intracellular expression of HLA-DR in PBMC of healthy controls and septic patients 
Intracellular HLA-DR was measured in permeabilised cells to investigate the presence of HLA-DR 
retained within the PBMC population. Flow cytometric measurement of HLA-DR expression in 
permeabilised cells measures both intracellular and surface. A comparison to the surface value allowed 
an estimate of intracellular versus extracellular expression of HLA-DR. Healthy controls (n=6) had 
lower expression of intracellular HLA-DR than septic patients. Figure 2 shows the  intracellular and 
surface expression of HLA-DR from septic patients and healthy controls. In septic patients the 
intracellular expression was significantly higher than the corresponding surface expression, P=0.01. For 
healthy controls the level of intracellular expression was not statistically different to the surface 
expression, p=0.85, (paired Students T Test). Septic patients had a higher intracellular expression of 
HLA-DR than healthy controls. 
Fluorescent microscopy was used with confocal imaging to allow visualisation of sections through 
the cell to observe surface and intracellular staining. Figures 3a-d show the intracellular and surface 
staining of PBMC in a healthy control and from a septic patient. These images illustrated a high 
intracellular expression of HLA-DR within the PBMC in septic patients where surface expression was 
barely visible. 
Plasma sHLA-DR levels in septic patients versus healthy controls.  
When sHLA-DR was measured in the plasma, healthy controls had a lower levels than both septic 
survivors and non-survivors, p =0.014, (Kruskall Wallis Test for 3 independent samples (Figure 4). The 
septic survivors showed a trend of higher levels of sHLA-DR than the non-survivors when the sHLA-
DR was measured over the three days, but this was not statistically significant.                              
HL-60 culture with GM-CSF 
HL-60 cells were used as an in vitro model to study the effects of GM-CSF on HLA-DR 
expression. HL-60 cells constitutively expressed surface HLA-DR which was measured using flow 
cytometry as previously described. GM-CSF did not significantly affect HLA-DR expression at 4 or 8 
hours incubation. 
Using limited dilution PCR techniques it was found that, when the HL-60 cells were cultured in 
the presence of GM-CSF, the HLA-DR mRNA was increased after 2, 4, 6 and 8 hours. These results 
indicated that GM-CSF was able to upregulate significantly HLA-DR expression at the level of gene 
transcription, which was detectable from 2 hours, p=0.02. (Figure 5). 
When the supernatants of the HL-60 cells, which were cultured with GM-CSF, were assayed for 
sHLA-DR there was a significant dose dependent increase in sHLA-DR, p=0.04 Friedman test. (Figure 
6). 
4.  Discussion  
A lowered expression of both the percentage of monocytes expressing HLA-DR and the density of 
HLA-DR expression have been observed as a feature of sepsis [4;5;7;8;22-25]. Only recently have the 
possible mechanisms for lowered HLA-DR expression been investigated. Ditschkowski et al. (1999) 
investigated the presence of  circulating sHLA-DR in sepsis and suggested that shedding of HLA-DR 
could be responsible for the lowered expression of HLA-DR.  Fumeaux et al. (2002) have recently 
described a post-translational modification of HLA-DR which may be responsible for a lowered cell 
surface expression of HLA-DR preventing expression to the cell surface and leading to accumulation in 
the cytoplasm. In this study it was also proposed that the cytokine which may be mediating this could 
be IL-10, and that the transcriptional expression of HLA-DR mRNA was not altered in sepsis. In the 
present study, it has been demonstrated that the transcription of HLA-DR in septic patients was 
significantly lowered early in sepsis (days 0 and 3) compared with healthy control levels. Interestingly Int. J. Med. Sci. 2004 1(3): 126-136  131 
the levels started to return closer to normal levels by day 14. The effect of GM-CSF on this 
transcriptional regulation was investigated. We had previously demonstrated GM-CSF could upregulate 
surface expression of HLA-DR in septic patients’ monocytes and we also showed that poor prognosis in 
these patients was associated with low plasma GM-CSF [20]. As GM-CSF has been suggested to be an 
important immunomodulatory cytokine in sepsis, we investigated its action on regulation of HLA-DR at 
the level of transcription and shedding. Recombinant human GM-CSF has been shown to reduce 
mortality in neonatal sepsis with neutropenia [19] and in vitro work has demonstrated that GM-CSF 
was able to restore or boost the function of human monocytes [18]. For example GM-CSF has been 
shown to stimulate monocyte TNF and TNF-receptor secretion [27]. GM-CSF has also been shown to 
normalise monocyte HLA-DR expression in septic patients with low monocyte HLA-DR expression [2] 
and septic neonates [18], as well as enhancing production of monocyte reactive oxygen species [17]. 
When the cell line, HL-60, was cultured with GM-CSF we demonstrated that an up-regulation of HLA-
DR mRNA was observed from 2 hours culture and at time points 4, 6 and 8 hours. Transcriptional 
regulation of HLA-DR by IFN-γ has previously been reported [10] and the present study indicates that 
GM-CSF is also able to regulate HLA-DR at the level of transcription. 
To investigate whether a post-translational modification was a mechanism involved in the 
regulation of HLA-DR, as described in the study of Fumeaux et al. (2002), flow cytometry and 
immunoflourescence were used to determine intracellular HLA-DR expression in healthy and septic 
patients. To investigate whether high levels of HLA-DR were expressed intracellulary in septic patients, 
patients were selected having a low surface expression (<30% of monocytes expressing HLA-DR). It 
was demonstrated in septic patients, that a higher number of cells expressed intracellular rather than 
surface cell surface HLA-DR. On the cytospins, it was further demonstrated that there was high 
intracellular HLA-DR expression compared with the respective surface expression. Our results support 
the observations seen in the study of Fumeaux et al. (2002) demonstrating that a modification of HLA-
DR, post-translationally, may be one mechanism responsible for the low surface expression of 
monocyte HLA-DR. 
When shed sHLA-DR was measured in plasma, significantly higher levels were observed in the 
septic patients, compared with healthy controls. This suggests that HLA-DR may be shed in sepsis. 
These results were in contrast to a previous study [11] which reported a significantly lower 
concentration of plasma sHLA-DR in septic patients when compared with non-septic ICU patients. 
However, in this study, no healthy controls were included, a normal level was not established and it was 
possible that both groups had high sHLA-DR levels. As a normal level was not established it is not 
possible to directly compare those results with our own.  However, in the non-septic ICU patients in 
that study, [11] the concentrations of sHLA-DR were over 1ug/ml, whereas in our patients and controls 
we never found concentrations over 0.5ug/ml.  In our study, higher levels have been observed in the 
plasma of septic patients, however this cannot be directly linked to this being shed from the surface of 
monocytes, as B cells, activated T cells and dendritic cells also express HLA-DR on their surface [3].  
To assess the relative contribution of shed to total HLA-DR, the sHLA-DR in the plasma was 
compared to the total HLA-DR present in cell. The level in the plasma (40ul neat) was far less than the 
level of HLA-DR in the cell lysates (5ul of a 1 in 10 dilution, from 2 x 10
6 PBMC). The shed HLA-DR 
therefore seemed to represent a small fraction of the total HLA-DR of the cell, however the function of 
these shed HLA-DR molecules remains to be investigated with respect to any potential role in sepsis. 
Serum sHLA-DR has been reported to be increased in infections and in inflammatory diseases or 
diseases with an activated immune profile. For example, in rheumatoid arthritis, sHLA-DR in synovial 
fluid correlated with disease activity [27; 28]. Raised synovial fluid sHLA-DR has also been reported to 
be associated in joint inflammatory disease [9] and high levels of sHLA-DR have been associated with 
viral infection [29]. The high levels of sHLA-DR in septic patients compared with healthy controls may 
therefore be indicative of infection and their response to inflammation. Further evidence for this was the 
dose- dependant increase in shedding of HL-60 HLA-DR upon incubation with the inflammatory 
mediator GM-CSF. 
The present study has elucidated some of the mechanisms by which HLA-DR expression in 
regulated in sepsis. The demonstration that GM-CSF increased the shedding of HLA-DR from the cell 
surface and also increased HLA-DR gene transcription may have implications for the therapy of septic 
patients with GM-CSF as these trials have already begun [18;19;30;31]. Our findings are also relevant Int. J. Med. Sci. 2004 1(3): 126-136  132 
to the understanding of the mechanisms through which clinical improvement through such 
immunomodulatory therapies may occur. 
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Figures 
Figure 1: Densitometry plot of the HLA-DR mRNA of healthy controls and septic patients. * denotes 
significance between septic patients and healthy controls on days 0 and 3, p < 0.05, Mann Whittney U test. 
n=12 (septic patients) n=8 (healthy controls) 
 
Figure 2:  The intracellular: surface expression ratio of HLA-DR. A value above 1 shows a higher 
intracellular expression of HLA-DR compared to surface expression. Septic patients show a significantly 
higher number of PBMC expressing HLA-DR when intracellular expression is measured, compared to 
surface expression, p=0.01. (MFI: Median Fluorescent intensity) 
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Figure 3:   (a) Fluorescent image of intracellular staining of a section through PBMC from a healthy control 
for HLA-DR expression. (b) The fluorescent image of a section though healthy control PBMC showing the 
surface expression of HLA-DR. (c)  Fluorescent image of intracellular staining for HLA-DR of a section 
through PBMC from a septic patient. (d)  shows the weak surface staining of HLA-DR in the same patients’ 
PBMC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Soluble HLA-DR in plasma from healthy controls and septic patients, divided into survivors and 
non-survivors, measured on the day 0 of the diagnosis of sepsis. P=0.014, healthy controls versus survivors 
and non-survivors (Kruskall Wallis test for 3 independent samples). 
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Figure 5:  The PCR results expressed by densitometry values of HL-60 cells treated with GM-CSF at 
concentrations of 1ng/ml and 0.1ng/ml. A linear trend exists over time when cells were treated with 0.1ng/ml 
(R
2 = 0.99). 
 
Figure 6:  The percentage change from control of soluble HLA-DR detected in cells cultured with GM-CSF 
and in media alone (control) after 8 hours incubation with GM-CSF (n=7). A significant dose dependant 
trend was observed, p = 0.04, Friedman test.  
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